Alan Bryce discusses PT-112, a platinum-containing drug with immunogenic cell death mechanism and osteotropic properties, with Oliver Sartor. The phase-two dose-finding study enrolled heavily ...
Pedro Barata is joined by Brian Shuch to discuss his investigator-initiated phase 2 trial evaluating girentuximab PET-CT imaging for detecting residual disease after nephrectomy in clear cell renal ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Laser technology has rapidly propelled surgical techniques in urinary tract calculus removal. The thulium fiber laser (TFL) is a relatively new tool that can be used for laser lithotripsy, as an ...
Read the Full Video Transcript Andrea Miyahira: Hi, everyone. I'm Andrea Miyahira with the Prostate Cancer Foundation. Thank you for joining me for a special Women in Science episode. And joining me ...
At the 2025 UCSF-UCLA PSMA Conference, Tanya Stoyanova discusses TROP2 as a promising alternative target for prostate cancer imaging and radiotherapy. She highlights that 25% of metastatic ...
Read the Full Video Transcript Ashish Kamat: Hello everybody, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, professor of urologic oncology at M.D. Anderson Cancer ...
At the 2025 UCSF-UCLA PSMA Conference, Matthias Eiber discusses lutetium PSMA therapy beyond six standard cycles. He distinguishes between extended treatment (continuous administration) and ...
Zachary Klaassen speaks with Alicia Morgans about examining the impact of PSA doubling time awareness on treatment decisions for high-risk biochemical recurrence. Dr. Morgans discusses findings from a ...
Read the Full Video Transcript Neeraj Agarwal: Welcome to this episode of UroToday. I’m Dr. Neeraj Agarwal, Professor of Medicine and Director of the Genitourinary Oncology program at the Huntsman ...
Comparing EMBARK vs EAU High-Risk Biochemical Recurrence Criteria in Prostate Cancer - Ugo Falagario
Zachary Klassen speaks with Ugo Falagario about identifying high-risk biochemical recurrence (BCR) after prostate cancer treatment. Dr. Falagario discusses findings from an analysis of the Stockholm-0 ...
Sam Chang speaks with Sarah Psutka about an expanded access program for cretostimogene (CG0070) in BCG-unresponsive non-muscle invasive bladder cancer. Dr. Psutka explains that this oncolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback